Nasdaq Losers: Synthesis Energy Systems (NASDAQ:SYMX), Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), Tiptree Financial Inc (NASDAQ:TIPT), Genocea Biosciences (NASDAQ:GNCA), Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Posted by on Jul 02, 2014

On May 28, 2014, Synthesis Energy Systems, Inc. (NASDAQ:SYMX), announced that its wholly owned subsidiary, SES Technologies, LLC, Shanghai-based Jiangsu Tianwo-SES Clean Energy Technologies Ltd. (TSEC), and Midrex Technologies, Inc. (Midrex), a subsidiary of Kobe Steel Limited (KBSTY), have entered into an exclusive agreement for the joint marketing of coal gasification-based direct reduced iron (DRI) facilities in China. These facilities will combine the premiere SES Gasification Technology with the industry-leading MIDREX(R) Direct Reduction Process to create syngas from low quality coals in order to convert iron ore into high-purity DRI. Synthesis Energy Systems, Inc. (NASDAQ:SYMX), weekly performance is 13.07%. On last trading day company shares ended up $1.73. Analysts mean target price for the company is $3.00. Synthesis Energy Systems, Inc. (NASDAQ:SYMX), distance from 50-day simple moving average (SMA50) is 4.29%.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), announced preclinical data Monday morning demonstrating the promise of DCR-PH1, for the treatment of primary hyperoxaluria type 1, a rare inherited liver disorder. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), fell 6.82% in last trading session and ended the day on $21.03. DRNA, return on assets is -51.90%. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), quarterly performance is -20.67%.

On May 14, 2014, Tiptree Financial Inc (NASDAQ:TIPT), announced its financial results for the first quarter ended March 31, 2014. “First quarter results were tempered by both unrealized losses in the form of lower mark-to-market values for our securities portfolio and investments in future profitability in the form of higher non-recurring expenses at certain subsidiaries,” said Geoffrey Kauffman, President and Chief Executive Officer of Tiptree. “However, we are pleased with Tiptree’s approximately 2% increase in Economic Book Value per share for the quarter, which was generally in line with the performance of broad market indices. As always, we intend to maintain our disciplined investment approach and our focus on long-term shareholder value.” Tiptree Financial Inc (NASDAQ:TIPT), shares moved down 5.17% in last trading session and was closed at $8.25, while trading in range of $8.10 – 8.64. Tiptree Financial Inc (NASDAQ:TIPT), year to date (YTD) performance is 12.40%.

On June 23, 2014, Genocea Biosciences Inc (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. Based on these data, the Company plans to advance GEN-004 into a Phase 2a trial in the third quarter of 2014. Genocea Biosciences Inc (NASDAQ:GNCA), ended the last trading day at $17.56. Company weekly volatility is calculated as 10.27% and price to cash ratio as 4.62. Genocea Biosciences Inc (NASDAQ:GNCA), showed a negative weekly performance of 15.48%.

On June 18, 2014, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), announced that the Company is set to join the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), weekly performance is -1.64%. On last trading day company shares ended up $2.40. Analysts mean target price for the company is $4.50. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), distance from 50-day simple moving average (SMA50) is 12.65%.

Leave a Reply

Your email address will not be published. Required fields are marked *